Fischer R - Search Results

1

Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting.

Del Vecchio GC, Crollo E, Schettini F, Schettini F, Fischer R, De Mattia D. Del Vecchio GC, et al. Among authors: fischer r. Acta Haematol. 2000;104(2-3):99-102. doi: 10.1159/000039759. Acta Haematol. 2000. PMID: 11154982

2

The influence of hemochromatosis mutations on iron overload of thalassemia major.

Longo F, Zecchina G, Sbaiz L, Fischer R, Piga A, Camaschella C. Longo F, et al. Among authors: fischer r. Haematologica. 1999 Sep;84(9):799-803. Haematologica. 1999. PMID: 10477452

3

Long-term treatment with deferiprone in a L1 veteran.

Meo A, Ruggeri A, La Rosa MA, Zanghì L, Kordes U, Fischer R. Meo A, et al. Among authors: fischer r. Eur J Haematol. 2005 Jun;74(6):523-5. doi: 10.1111/j.1600-0609.2005.00413.x. Eur J Haematol. 2005. PMID: 15876257

4

A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia.

Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, Voi V, Lund U, Tricta F. Galanello R, et al. Among authors: fischer r. Haematologica. 2006 Sep;91(9):1241-3. Haematologica. 2006. PMID: 16956824 Clinical Trial.

5

Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry.

Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Fischer R, et al. Br J Haematol. 2003 Jun;121(6):938-48. doi: 10.1046/j.1365-2141.2003.04297.x. Br J Haematol. 2003. PMID: 12786807 Free article.

6

Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia.

Harmatz P, Jonas MM, Kwiatkowski JL, Wright EC, Fischer R, Vichinsky E, Giardina PJ, Neufeld EJ, Porter J, Olivieri N; Thalassemia Clinical Research Network. Harmatz P, et al. Among authors: fischer r. Haematologica. 2008 Aug;93(8):1247-51. doi: 10.3324/haematol.12352. Epub 2008 Jun 12. Haematologica. 2008. PMID: 18556414 Free article. Clinical Trial.

7

Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.

Fischer R, Engelhardt R. Fischer R, et al. Lancet. 2003 Jan 11;361(9352):182-3; author reply 183-4. doi: 10.1016/S0140-6736(03)12222-2. Lancet. 2003. PMID: 12531618 No abstract available.

8

Pituitary iron and factors predictive of fertility status in transfusion dependent thalassemia.

Singer ST, Fischer R, Allen I, Lal A, Vichinsky E, Yuan Q, Wang ZJ. Singer ST, et al. Among authors: fischer r. Haematologica. 2021 Jun 1;106(6):1740-1744. doi: 10.3324/haematol.2020.252726. Haematologica. 2021. PMID: 33121232 Free PMC article.

9

Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone.

Nielsen P, Fischer R, Engelhardt R, Tondüry P, Gabbe EE, Janka GE. Nielsen P, et al. Among authors: fischer r. Br J Haematol. 1995 Dec;91(4):827-33. doi: 10.1111/j.1365-2141.1995.tb05396.x. Br J Haematol. 1995. PMID: 8547125

10

Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.

Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swerdlow P, Coates T, Lane P, Files B, Mueller BU, Coïc L, Forni GL, Fischer R, Marks P, Rofail D, Abetz L, Baladi JF. Vichinsky E, et al. Among authors: fischer r. Acta Haematol. 2008;119(3):133-41. doi: 10.1159/000125550. Epub 2008 Apr 11. Acta Haematol. 2008. PMID: 18408362 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,333 results

Search Page

Filters